BGNE vs. TAK, ALNY, TEVA, GMAB, RPRX, BMRN, VTRS, UTHR, SRPT, and RDY
Should you be buying BeiGene stock or one of its competitors? The main competitors of BeiGene include Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry.
Takeda Pharmaceutical (NYSE:TAK) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, community ranking, risk and media sentiment.
Takeda Pharmaceutical has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Takeda Pharmaceutical has a net margin of 6.18% compared to Takeda Pharmaceutical's net margin of -28.39%. BeiGene's return on equity of 9.92% beat Takeda Pharmaceutical's return on equity.
Takeda Pharmaceutical has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
BeiGene received 440 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 69.14% of users gave BeiGene an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Takeda Pharmaceutical currently has a consensus price target of $14.00, indicating a potential upside of 4.87%. BeiGene has a consensus price target of $251.93, indicating a potential upside of 69.25%. Given Takeda Pharmaceutical's higher possible upside, analysts plainly believe BeiGene is more favorable than Takeda Pharmaceutical.
9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 48.6% of BeiGene shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 7.4% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, BeiGene had 2 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for BeiGene and 6 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.32 beat BeiGene's score of 0.29 indicating that BeiGene is being referred to more favorably in the news media.
Summary
BeiGene beats Takeda Pharmaceutical on 10 of the 17 factors compared between the two stocks.
Get BeiGene News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
